Clinical Trials List
2016-06-01 - 2024-06-28
Phase III
Terminated6
ICD-10C66.2
Malignant neoplasm of left ureter
ICD-10C67
Malignant neoplasm of bladder
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Yeong-Shiau Pu Division of Urology
- - - Division of Urology
- JHE-CYUAN GUO Division of Hematology & Oncology
- - - Division of Urology
- CHUNG-HSIN CHEN Division of Urology
- Ying-Chun Shen Division of Hematology & Oncology
- Chia-Chi Lin Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Audit
None
Co-Principal Investigator
- Shang-Yin Wu Division of General Internal Medicine
- Wu-Chou Su Division of General Internal Medicine
- Sin-Syue Li Division of General Internal Medicine
- Wei-Pang Chung Division of General Internal Medicine
- Yu-Min Yeh Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Terminated
Audit
None
Co-Principal Investigator
- 陳彥仰 Division of Hematology & Oncology
- Tai-Jan Chiu Division of Hematology & Oncology
- 劉建廷 Division of Hematology & Oncology
- Shau-Hsuan Li Division of Hematology & Oncology
- 陳彥豪 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Che-Hung Lin Division of Hematology & Oncology
- Ching-Chan Lin Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Cheng-Kuang Yang Division of Urology
- 熊小澐 Division of Radiology
- Shian-Shiang Wang Division of Urology
- Cheng-Che Chen Division of Urology
- Chuan-Shu Chen Division of Urology
- 裘坤元 Division of Urology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
Audit
None
Taiwan National PI
Co-Principal Investigator
- Po-Jung Su Division of Hematology & Oncology
- See-Tong Pang Division of Hematology & Oncology
- Yung-Chia Kao Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
1 Terminated
Audit
None
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
30 participants
-
Global
1200 participants
